| 產品名稱 | HUVEC/TERT 2 |
|---|---|
| 商品貨號 | B216124 |
| Organism | Homo sapiens, human |
| Tissue | Umbilical vascular endothelium |
| Cell Type | Endothelial cell immortalized with hTERT |
| Product Format | frozen 1 mL |
| Morphology | Cobblestone appearance with large dark nuclei |
| Culture Properties | adherent |
| Biosafety Level | 2 [These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens.
ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223. Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.] Human Material Precaution All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome. Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Normal |
| Age | Newborn |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | Immune response, wound healing, cellular response to viral or bacterial infection, oxidative stress, angiogenesis, arteriolosclerosis, drug screening, tubule formation |
| Shipping Information | Frozen 1 mL |
| Storage Conditions | -130°C |
| Karyotype | 46,XX,add(14)(p10) |
| Images |  |
| Derivation | Umbilical vascular endothelium transduced with hTERT |
| Antigen Expression | CD31 >75% positive |
| Receptor Expression | LDL uptake >75%positive |
| Complete Growth Medium | The base medium for this cell line is Vascular Cell Basal Medium (ATCC® PCS-100-030), supplemented with Vascular Endothelial Cell Growth Kit-VEGF (ATCC® PCS-100-041). Alternatively, the Vascular Cell Basal Medium can be supplemented with Endothelial Cell Growth Kit-BBE (ATCC® PCS-100-040). |
| Subculturing | Every 3-4 days at 8000 cells/cm2
Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation solutions for culture vessels of other sizes.
|
| Cells per Vial | 1.2 x 106 cells/vial |
| Volume | 1 mL |
| STR Profile | Amelogenin: X
CSF1PO: 12 D5S818: 15, 16 D7S820: 9, 11 D13S317: 11, 12 D16S539: 9, 13 TH01: 6, 9 TPOX: 8, 9 vWA: 16, 19 CO1 Species: Human |
| Sterility Tests | Bacteria and Yeast: Negative Mycoplasma: Negative |
| Viability | >70% when thawed from cryopreservation |
| Population Doubling Capacity | At least 25 PDL |
| Population Doubling Time | 2.5 days |
| Name of Depositor | Evercyte |
| Year of Origin | 2011 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
